Skip to main content
Top
Published in: Neurocritical Care 3/2011

01-06-2011 | Review Article

Locally-administered Intrathecal Thrombolytics Following Aneurysmal Subarachnoid Hemorrhage: A Systematic Review and Meta-analysis

Authors: Andreas H. Kramer, Jeffrey J. Fletcher

Published in: Neurocritical Care | Issue 3/2011

Login to get access

Abstract

Background

The volume and clearance rate of blood in the basal cisterns and ventricles are important predictors of complications following aneurysmal subarachnoid hemorrhage (SAH). Thus, there is a strong rationale for interventions aimed at accelerating the clearance of blood.

Methods

We systematically searched MEDLINE, EMBASE, Cochrane databases, references of review articles and gray literature sources to identify randomized controlled trials (RCTs) assessing the efficacy of locally-administered, intrathecal thrombolytics in patients with SAH. Primary outcomes included the occurrence of poor neurologic recovery and delayed neurologic deficits (DNDs). Secondary outcomes included angiographic vasospasm, chronic hydrocephalus and treatment-related complications. Data were extracted and appraised independently and in duplicate, using standardized forms. Fixed or random effects models, as appropriate based on the degree of study heterogeneity were applied to calculate summary measures.

Results

Five RCTs, enrolling 465 patients, met eligibility criteria. The methodology, results and risk of bias varied considerably across individual studies. Overall, use of intrathecal thrombolytics was associated with significant reductions in the development of poor outcomes (OR 0.52, 0.34–0.78, P < 0.01), DNDs (OR 0.54, 0.34–0.87, P = 0.01), angiographic vasospasm (OR 0.32, 0.15–0.70, P < 0.01) and chronic hydrocephalus (OR 0.33, 0.15–0.74, P < 0.01), without any increment in hemorrhagic or infectious complications. These findings were dampened by the exclusion of a study which concomitantly administered intrathecal vasodilators and thrombolytics.

Conclusions

Current data suggests that intrathecal thrombolytics improve outcomes following SAH. However, there are important limitations to existing RCTs, with considerable risk of bias. Further standardization of techniques and evaluation in larger, more rigorous RCTs is required.
Appendix
Available only for authorised users
Literature
1.
go back to reference Feigin VL, Lawes CMM, Bennett DA, Barker-Collo SL, Parag V. Worldwide stroke incidence and early case fality reported in 56 population-based studies: a systematic review. Lancet Neurology. 2009;8:355–69.PubMedCrossRef Feigin VL, Lawes CMM, Bennett DA, Barker-Collo SL, Parag V. Worldwide stroke incidence and early case fality reported in 56 population-based studies: a systematic review. Lancet Neurology. 2009;8:355–69.PubMedCrossRef
2.
go back to reference Mayer SA, Kreiter KT, Copeland D, Bernardini GL, Bates JE, Peery S, Claassen J, Du YE, Connolly ES Jr. Global and domain-specific cognitive impairment and outcome after subarachnoid hemorrhage. Neurology. 2002;59:1750–8.PubMed Mayer SA, Kreiter KT, Copeland D, Bernardini GL, Bates JE, Peery S, Claassen J, Du YE, Connolly ES Jr. Global and domain-specific cognitive impairment and outcome after subarachnoid hemorrhage. Neurology. 2002;59:1750–8.PubMed
3.
go back to reference Rosengart AJ, Schultheiss KE, Tolentino J, Macdonald RL. Prognostic factors for outcome in patients with aneurysmal subarachnoid hemorrhage. Stroke. 2007;38:2315–21.PubMedCrossRef Rosengart AJ, Schultheiss KE, Tolentino J, Macdonald RL. Prognostic factors for outcome in patients with aneurysmal subarachnoid hemorrhage. Stroke. 2007;38:2315–21.PubMedCrossRef
4.
go back to reference Sheehan JP, Polin RS, Sheehan JM, Baskaya MK, Kassell NF. Factors associated with hydrocephalus after aneurysmal subarachnoid hemorrhage. Neurosurgery. 1999;45:1120–7.PubMedCrossRef Sheehan JP, Polin RS, Sheehan JM, Baskaya MK, Kassell NF. Factors associated with hydrocephalus after aneurysmal subarachnoid hemorrhage. Neurosurgery. 1999;45:1120–7.PubMedCrossRef
5.
go back to reference Macdonald RL, Rosengart A, Huo D, Karrison T. Factors associated with the development of vasospasm after planned surgical treatment of aneurysmal subarachnoid hemorrhage. J Neurosurg. 2003;99:644–52.PubMedCrossRef Macdonald RL, Rosengart A, Huo D, Karrison T. Factors associated with the development of vasospasm after planned surgical treatment of aneurysmal subarachnoid hemorrhage. J Neurosurg. 2003;99:644–52.PubMedCrossRef
6.
go back to reference Reilly C, Amidei C, Tolentino J, Jahromi BS, Macdonald RL. Clot volume and clearance rate as independent predictors of vasospasm after aneurysmal subarachnoid hemorrhage. J Neurosurg. 2004;101:255–61.PubMedCrossRef Reilly C, Amidei C, Tolentino J, Jahromi BS, Macdonald RL. Clot volume and clearance rate as independent predictors of vasospasm after aneurysmal subarachnoid hemorrhage. J Neurosurg. 2004;101:255–61.PubMedCrossRef
7.
go back to reference Pluta RM. Delayed cerebral vasospasm and nitric oxide: review, new hypothesis, and proposed treatment. Pharmacol Ther. 2005;105:23–56.PubMedCrossRef Pluta RM. Delayed cerebral vasospasm and nitric oxide: review, new hypothesis, and proposed treatment. Pharmacol Ther. 2005;105:23–56.PubMedCrossRef
8.
go back to reference Findlay JM, Weir BK, Steinke D, Tanabe T, Gordon P, Grace M. Effect of intrathecal thrombolytic therapy on subarachnoid clot and chronic vasospasm in a primate model of SAH. J Neurosurg. 1988;69:723–35.PubMedCrossRef Findlay JM, Weir BK, Steinke D, Tanabe T, Gordon P, Grace M. Effect of intrathecal thrombolytic therapy on subarachnoid clot and chronic vasospasm in a primate model of SAH. J Neurosurg. 1988;69:723–35.PubMedCrossRef
9.
go back to reference Amin-Hanjini S, Ogilvy CS, Barker FG 2nd. Does intracisternal thrombolysis prevent vasospasm after aneurysmal subarachnoid hemorrhage? A meta-analysis. Neurosurgery. 2004;54:326–34.CrossRef Amin-Hanjini S, Ogilvy CS, Barker FG 2nd. Does intracisternal thrombolysis prevent vasospasm after aneurysmal subarachnoid hemorrhage? A meta-analysis. Neurosurgery. 2004;54:326–34.CrossRef
10.
go back to reference Hanley DF. Intraventricular hemorrhage: severity factor and treatment target in spontaneous intracerebral hemorrhage. Stroke. 2009;40:1533–8.PubMedCrossRef Hanley DF. Intraventricular hemorrhage: severity factor and treatment target in spontaneous intracerebral hemorrhage. Stroke. 2009;40:1533–8.PubMedCrossRef
11.
go back to reference Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264–9.PubMed Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264–9.PubMed
12.
13.
go back to reference Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trial. 1996;17:1–12.CrossRef Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trial. 1996;17:1–12.CrossRef
14.
go back to reference Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273:408–12.PubMedCrossRef Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273:408–12.PubMedCrossRef
15.
go back to reference Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.PubMedCrossRef Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.PubMedCrossRef
16.
go back to reference Egger M, Smith GD. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.PubMed Egger M, Smith GD. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.PubMed
17.
go back to reference Kanamura K, Waga S, Sakakura M, Morikawa A, Yamamoto Y, Morooka Y, Okada M. Comparative study of cisternal lavage methods for the treatment of cerebral vasospasm. In: Cerebral Vasospasm. Proceedings of the 5th international conference, Findlay JM, editor. Amsterdam: Elsevier;1993. p 471–473. Kanamura K, Waga S, Sakakura M, Morikawa A, Yamamoto Y, Morooka Y, Okada M. Comparative study of cisternal lavage methods for the treatment of cerebral vasospasm. In: Cerebral Vasospasm. Proceedings of the 5th international conference, Findlay JM, editor. Amsterdam: Elsevier;1993. p 471–473.
18.
go back to reference Findlay JM, Kassell NF, Weir BK, Haley EC Jr, Kongable G, Germanson T, Truskowski L, Alves WM, Holness RO, Knuckey NW. A randomized trial of intraoperative, intracisternal tissue plasminogen activator for the prevention of vasospasm. Neurosurgery. 1995;37:168–76.PubMedCrossRef Findlay JM, Kassell NF, Weir BK, Haley EC Jr, Kongable G, Germanson T, Truskowski L, Alves WM, Holness RO, Knuckey NW. A randomized trial of intraoperative, intracisternal tissue plasminogen activator for the prevention of vasospasm. Neurosurgery. 1995;37:168–76.PubMedCrossRef
19.
go back to reference Hamada J, Kai Y, Morioka M, Yano S, Mizuno T, Hirano T, Kazekawa K, Ushio Y. Effect on cerebral vasospasm of coil embolization followed by microcatheter intrathecal urokinase infusion into the cistern magna: a prospective randomized study. Stroke. 2003;34:2549–54.PubMedCrossRef Hamada J, Kai Y, Morioka M, Yano S, Mizuno T, Hirano T, Kazekawa K, Ushio Y. Effect on cerebral vasospasm of coil embolization followed by microcatheter intrathecal urokinase infusion into the cistern magna: a prospective randomized study. Stroke. 2003;34:2549–54.PubMedCrossRef
20.
go back to reference Li YH, Guo K, Zi XH, Song Z. Combining exchange of cerebrospinal fluid with small dose of urokinase injection for subarachnoid hemorrhage. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2005;30:217–20.PubMed Li YH, Guo K, Zi XH, Song Z. Combining exchange of cerebrospinal fluid with small dose of urokinase injection for subarachnoid hemorrhage. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2005;30:217–20.PubMed
21.
go back to reference Hanggi D, Eicker S, Beseoglu K, Behr J, Turowski B, Steiger HJ. A multimodal concept in patients after severe aneurysmal subarachnoid hemorrhage: results of a controlled single centre prospective randomized multimodal phase I/II trial on cerebral vasospasm. Cen Eur Neurosurg. 2009;70:61–7.PubMedCrossRef Hanggi D, Eicker S, Beseoglu K, Behr J, Turowski B, Steiger HJ. A multimodal concept in patients after severe aneurysmal subarachnoid hemorrhage: results of a controlled single centre prospective randomized multimodal phase I/II trial on cerebral vasospasm. Cen Eur Neurosurg. 2009;70:61–7.PubMedCrossRef
22.
go back to reference Klimo P, Kestle JR, MacDonald JD, Schmidt RH. Marked reduction of cerebral vasospasm with lumbar drainage of cerebrospinal fluid after subarachnoid hemorrhage. J Neurosurg. 2004;100:215–24.PubMedCrossRef Klimo P, Kestle JR, MacDonald JD, Schmidt RH. Marked reduction of cerebral vasospasm with lumbar drainage of cerebrospinal fluid after subarachnoid hemorrhage. J Neurosurg. 2004;100:215–24.PubMedCrossRef
23.
go back to reference Hariton GB, Findlay JM, Weir BK, Kasuya H, Grace MG, Mielke BW. Comparison of intrathecal administration of urokinase and tissue plasminogen activator on subarachnoid clot and chronic vasospasm in a primate model. Neurosurgery. 1993;33:691–6.PubMedCrossRef Hariton GB, Findlay JM, Weir BK, Kasuya H, Grace MG, Mielke BW. Comparison of intrathecal administration of urokinase and tissue plasminogen activator on subarachnoid clot and chronic vasospasm in a primate model. Neurosurgery. 1993;33:691–6.PubMedCrossRef
24.
go back to reference Findlay JM, Weir BKA, Kanamuru K, Grace M, Baughman R. The effect of timing of intrathecal fibrinolytic therapy on cerebral vasospasm in a primate model of subarachnoid hemorrhage. Neurosurgery. 1990;26:201–6.PubMedCrossRef Findlay JM, Weir BKA, Kanamuru K, Grace M, Baughman R. The effect of timing of intrathecal fibrinolytic therapy on cerebral vasospasm in a primate model of subarachnoid hemorrhage. Neurosurgery. 1990;26:201–6.PubMedCrossRef
25.
go back to reference Zabramski JM, Spetzler RF, Lee KS, Papadopoulos SM, Bovill E, Zimmerman RS, Bederson JB. Phase I trial of tissue plasminogen activator for the prevention of vasospasm in patietns with aneurysmal subarachnoid hemorrhage. Neurosurgery. 1991;75(2):189–96.CrossRef Zabramski JM, Spetzler RF, Lee KS, Papadopoulos SM, Bovill E, Zimmerman RS, Bederson JB. Phase I trial of tissue plasminogen activator for the prevention of vasospasm in patietns with aneurysmal subarachnoid hemorrhage. Neurosurgery. 1991;75(2):189–96.CrossRef
26.
go back to reference Sasaki T, Ohta T, Kikuchi H, Takakura K, Usui M, Ohnishi H, Kondo A, Tanabe H, Nakamura J, Yamada K. A phase II clinical trial of recombinant human tissue-type plasminogen activator against cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Neurosurgery. 1994;35:597–604.PubMedCrossRef Sasaki T, Ohta T, Kikuchi H, Takakura K, Usui M, Ohnishi H, Kondo A, Tanabe H, Nakamura J, Yamada K. A phase II clinical trial of recombinant human tissue-type plasminogen activator against cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Neurosurgery. 1994;35:597–604.PubMedCrossRef
27.
go back to reference Findlay JM, Jacka MJ. Cohort study of intraventricular thrombolysis with recombinant tissue plasminogen activator for aneurysmal intraventricular hemorrhage. Neurosurgery. 2004;55:532–7.PubMedCrossRef Findlay JM, Jacka MJ. Cohort study of intraventricular thrombolysis with recombinant tissue plasminogen activator for aneurysmal intraventricular hemorrhage. Neurosurgery. 2004;55:532–7.PubMedCrossRef
28.
go back to reference Varelas PN, Rickert KL, Cusick J, Hacein-Bey L, Sinson G, Torbey M, Spanaki M, Gennarelli TA. Intraventricular hemorrhage after aneurysmal subarachnoid hemorrhage: pilot study of treatment with intraventricular tissue plasminogen activator. Neurosurgery. 2005;56:205–13.PubMedCrossRef Varelas PN, Rickert KL, Cusick J, Hacein-Bey L, Sinson G, Torbey M, Spanaki M, Gennarelli TA. Intraventricular hemorrhage after aneurysmal subarachnoid hemorrhage: pilot study of treatment with intraventricular tissue plasminogen activator. Neurosurgery. 2005;56:205–13.PubMedCrossRef
29.
go back to reference Ramakrishna R, Sekhar LN, Ramanathan D, Temkin N, Hallam D, Ghodke BV, Kim LJ. Intraventricular tissue plasminogen activator for the prevention of vasospasm and hydrocephalus after aneurismal subarachnoid hemorrhage. Neurosurgery. 2010;67:110–7.PubMedCrossRef Ramakrishna R, Sekhar LN, Ramanathan D, Temkin N, Hallam D, Ghodke BV, Kim LJ. Intraventricular tissue plasminogen activator for the prevention of vasospasm and hydrocephalus after aneurismal subarachnoid hemorrhage. Neurosurgery. 2010;67:110–7.PubMedCrossRef
Metadata
Title
Locally-administered Intrathecal Thrombolytics Following Aneurysmal Subarachnoid Hemorrhage: A Systematic Review and Meta-analysis
Authors
Andreas H. Kramer
Jeffrey J. Fletcher
Publication date
01-06-2011
Publisher
Humana Press Inc
Published in
Neurocritical Care / Issue 3/2011
Print ISSN: 1541-6933
Electronic ISSN: 1556-0961
DOI
https://doi.org/10.1007/s12028-010-9429-z

Other articles of this Issue 3/2011

Neurocritical Care 3/2011 Go to the issue